Preclinical evaluation of targeted therapies in Sdhb-mutated tumors
Sophie Moog(Institut Gustave Roussy), Judith Favier(Inserm), Charlotte Lussey‐Lepoutre(Inserm), Estelle Robidel(Délégation Paris 5), Gwennhaël Autret(Inserm), Daniel Balvay(Délégation Paris 5), Y. Braik-Djellas(Inserm), Betty Salgues(Centre Hospitalier Edmond Garcin), Anne‐Paule Gimenez‐Roqueplo(Délégation Paris 5), Bertrand Tavitian(Inserm), Thomas Viel(Inserm)
Cited by 11
Related Papers
The ratio of the nucleon structure functions F2N for iron and deuterium
|Physics Letters B|1983|1.1k
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
|Cancer Cell|2017|791
SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma
|Cancer Cell|2013|772
SDHA is a tumor suppressor gene causing paraganglioma
|Human Molecular Genetics|2010|651
Search for neutrino oscillations at 15, 40 and 95 meters from a nuclear power reactor at Bugey
|Nuclear Physics B|1995|628